Mr. Wyzga has served as Chairman of the X4 Board of Directors since July 2018. Mr. Wyzga is currently the President of MSW Consulting Inc., a strategic consulting group focused in the lifesciences area. From December 2011 until November 2013, Mr. Wyzga served as President and Chief Executive Officer and a member of the board of directors of Radius Health, Inc., a publicly traded biopharmaceutical company. Prior to that, Mr. Wyzga served in various senior management positions at Genzyme Corporation, a publicly traded global biotechnology company. Mr. Wyzga joined Genzyme in February 1998 and most recently served as Executive Vice President, Finance from May 2003 until November 2011 and as chief financial officer from July 1999 until November 2011. From February 2014 to December 2018, Mr. Wyzga served as a member of the board of directors of Akebia Therapeutics, Inc., a publicly traded biopharmaceutical company, where he was also a member of the compensation committee and chair of the audit committee.
Since February 2015, Mr. Wyzga has also served as a member of the board of directors of Exact Sciences Corporation, a publicly traded medical technology company, where he is also a member of the audit and compensation committees. Since October 2013, Mr. Wyzga has also served as a member of the board of directors of Oncomed Pharmaceuticals, Inc., where he is also a member of the audit committee. Since February 2016, Mr. Wyzga has also served as Chairman of the board of directors of GenSight Biologics S.A., a Euronext traded biopharmaceutical company. Mr. Wyzga also previously served as a member of the board of directors of Idenix Pharmaceuticals, Inc., a publicly traded biotechnology company that was acquired by Merck in August 2014, where he also served as the chair of the audit committee and a member of the compensation committee, and as a member of the Supervisory Board of Prosensa Holding B.V., a publicly traded biopharmaceutical company, from June 2014 until the Prosensa acquisition by BioMarin Falcon B.V. in December 2014. He received an M.B.A. from Providence College and a B.S. from Suffolk University.
What is Michael S. Wyzga's net worth?
The estimated net worth of Michael S. Wyzga is at least $9.71 thousand as of August 18th, 2023. Mr. Wyzga owns 2,555 shares of X4 Pharmaceuticals stock worth more than $9,709 as of December 5th. This net worth approximation does not reflect any other investments that Mr. Wyzga may own. Learn More about Michael S. Wyzga's net worth.
How do I contact Michael S. Wyzga?
Has Michael S. Wyzga been buying or selling shares of X4 Pharmaceuticals?
Michael S. Wyzga has not been actively trading shares of X4 Pharmaceuticals during the last ninety days. Most recently, on Friday, August 18th, Michael S. Wyzga bought 833 shares of X4 Pharmaceuticals stock. The stock was acquired at an average cost of $36.00 per share, with a total value of $29,988.00. Following the completion of the transaction, the director now directly owns 2,555 shares of the company's stock, valued at $91,980. Learn More on Michael S. Wyzga's trading history.
Who are X4 Pharmaceuticals' active insiders?
Are insiders buying or selling shares of X4 Pharmaceuticals?
During the last twelve months, X4 Pharmaceuticals insiders bought shares 2 times. They purchased a total of 87,238 shares worth more than $252,556.76. During the last twelve months, insiders at the sold shares 4 times. They sold a total of 6,753 shares worth more than $91,165.50. The most recent insider tranaction occured on October, 23rd when Chairman Adam R Craig bought 86,206 shares worth more than $249,997.40. Insiders at X4 Pharmaceuticals own 2.4% of the company.
Learn More about insider trades at X4 Pharmaceuticals. Information on this page was last updated on 10/23/2025.
